Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor (CAR) T-

Related Keywords

California ,United States ,Aleida Pujol Morcillo ,Roxana Radu ,Edurne Mugarza ,Agustin Vega Crespo ,Jia Chen ,Antoni Ribas ,Yvonne Chen ,David Berger Manerio ,Sameeha Jilani ,Daniel Sanghoon Shin ,Jeffrey Chokry ,Ignacio Baselga Carretero ,Philip Scumpia ,Justin Saco ,Rubi Gupta ,Cristina Puig ,Gabriel Abril Rodriguez ,David Geffen School Of Medicine ,National Institutes Of Health ,Edythe Broad Center ,Department Of Defense ,Health Jonsson Comprehensive Cancer Center ,Nature Communications ,Melanoma Research Alliance ,Parker Institute For Cancer Immunotherapy ,Stem Cell Research ,California Institute For Regenerative Medicine ,Denise Heady ,Jonsson Comprehensive Cancer Center ,Cristina Puig Saus ,David Geffen School ,Regenerative Medicine ,Ami Pant ,Parker Institute ,California Institute ,National Institutes ,